Drugs & Therapy Perspectives

, Volume 21, Issue 8, pp 10–14 | Cite as

There is a smorgasbord of options in the management of dyslipidaemia in visceral obesity

Disease Management


  1. 1.
    Chan DC, Barrett HPR, Watts GF Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. Am J Cardiovasc Drugs 2004; 4(4): 227–46PubMedCrossRefGoogle Scholar
  2. 2.
    Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97CrossRefGoogle Scholar
  3. 3.
    Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747–57PubMedCrossRefGoogle Scholar
  4. 4.
    Haibert JA, Silagy CA, Finucane P, et al. Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr 1999; 53: 514–22CrossRefGoogle Scholar
  5. 5.
    Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284: 1263–70PubMedCrossRefGoogle Scholar
  6. 6.
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245–55PubMedCrossRefGoogle Scholar
  7. 7.
    Knopp RH, Gitter H, Truitt T. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003; 24: 729–41PubMedCrossRefGoogle Scholar
  8. 8.
    Paoletti R, Fahmy M, Mahla G, et al. Rosuvastatin demonstrates greater reduction of low density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001; 8: 383–90PubMedCrossRefGoogle Scholar
  9. 9.
    The Bezafibrate Infarction Prevention (BIP) Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102: 21–7CrossRefGoogle Scholar
  10. 10.
    Scott LJ, Curran MP, Figgit DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2003; 4(20): 117–138.Google Scholar
  11. 11.
    British national formulary. No. 49. London: The Pharmaceutical Press, 2005 MarGoogle Scholar
  12. 12.
    Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005; 111(23): 3051–7PubMedCrossRefGoogle Scholar
  13. 13.
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: Veterans Affairs high density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–8PubMedCrossRefGoogle Scholar
  14. 14.
    The Diabetes Atherosclerosis Intervention Study. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: a randomised study. Lancet 2001; 357: 905–10CrossRefGoogle Scholar
  15. 15.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45PubMedCrossRefGoogle Scholar
  16. 16.
    Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 1995; 92: 1779–85PubMedCrossRefGoogle Scholar
  17. 17.
    Grundy SM, Vega G, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002; 162: 1568–76PubMedCrossRefGoogle Scholar
  18. 18.
    Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80: 608–13PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Personalised recommendations